Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company
developing innovative ribonucleic acid (RNA) therapeutics, announced
today the closing of a CHF 6 million seed financing round. Versameb
further strengthens its team by the appointment of Dr. Klaas P.
Zuideveld as Chief Development Officer effective May 1 to advance its
lead molecule into clinical development. Versameb is engaged in the
discovery and development of next-generation RNA-based drugs using
its proprietary VERSagile technology platform.
Management team joined by Chief Development Officer (CDO)
Versameb appointed Dr. Klaas P. Zuideveld as CDO. Most recently, Dr.
Zuideveld held the position of Vice President Pharmaceutical
partnerships at Caris Life Sciences, where he was responsible for the
company's first companion diagnostic partnership and precision
medicine led clinical trials. Prior to that, Dr. Zuideveld held
leadership positions in drug development and consulted for Pharsight
(acquired by Certara), F. Hoffmann-La Roche, Mosaic Biomedicals
(acquired by Northern Biologics) and Therachon (acquired by Pfizer).
He holds a Ph.D. from the University of Leiden, The Netherlands.
"Klaas brings a rare combination of scientific excellence and strong
operational expertise to this role. With his extensive experience in
developing therapeutics from early discovery stages through clinical
trials, he will oversee Versameb's preclinical and clinical
development as the company advances towards planning and executing
clinical development programs" commented Prof. Dr. Friedrich Metzger,
Chief Executive Officer and Co-founder of Versameb.
The VERSagile platform - Programming mRNA sequences for improved
Versameb developed a unique proprietary molecular algorithm that has
the potential to make mRNA therapies more effective. Molecular
engineering mRNA sequences with the VERSagile technology platform
generates molecules optimized for improved protein secretion and
allows for modulation of different therapeutic targets. Versameb
currently develops molecules targeting regulation of immune response
or regeneration in the fields of dermatology, oncology and myology.
The platform has been validated for these therapeutic targets and
preclinical proof of principle has been established with its lead
asset in animal models. The proceeds of the latest financing round
will be used to progress its lead asset towards clinic by the end of
2021 and advance additional applications in therapeutic areas of high
unmet medical need, creating an attractive and balanced portfolio.
Dr. Reinhard Ambros, the company's Chairman of the Board and former
Head of the Novartis Venture fund, stated: "Versameb has reached
important milestones in developing a highly transformative, well
differentiated technology platform. I am very pleased to see that the
company is attracting excellent talent to perform on our strategic
and operational goals and that it is enjoying strong support from its
About Versameb AG
Versameb AG is a preclinical-stage biopharmaceutical company located
in Basel, Switzerland managed by an experienced scientific and
The company's focus is the development of novel RNA-based
therapeutics. Versameb's proprietary VERSagile technology platform
enables efficient development of functional mRNA molecules in
multiple disease areas with high unmet medical need including
dermatology, oncology and myology.
For more information, please visit www.versameb.com.
Digital press kit: http://www.ots.at/pressemappe/CH137145/aom
Aktien auf dem Radar:Semperit, Frequentis, Kapsch TrafficCom, Rosenbauer, FACC, Zumtobel, Wienerberger, voestalpine, UBM, RBI, Uniqa, ATX, ATX Prime, Verbund, VIG, Lenzing, Österreichische Post, OMV, Addiko Bank, Rosgix, DO&CO, Polytec, Stadlauer Malzfabrik AG, Deutsche Post, adidas, E.ON , Deutsche Telekom, Bayer, Münchener Rück, HeidelbergCement, Continental.
Die Österreichische Post ist der landesweit führende Logistik- und Postdienstleister. Zu den Hauptgeschäftsbereichen zählen die Beförderung von Briefen, Werbesendungen, Printmedien und Paketen. Das Unternehmen hat Tochtergesellschaften in zwölf europäischen Ländern.
>> Besuchen Sie 56 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER